A detailed history of Federated Hermes, Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 2,740,765 shares of NTLA stock, worth $33.4 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares
2,740,765
Previous 2,300,889 19.12%
Holding current value
$33.4 Million
Previous $51.5 Million 9.38%
% of portfolio
0.13%
Previous 0.12%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$19.72 - $27.36 $8.67 Million - $12 Million
439,876 Added 19.12%
2,740,765 $56.3 Million
Q2 2024

Aug 08, 2024

BUY
$20.02 - $27.22 $7.43 Million - $10.1 Million
371,189 Added 19.24%
2,300,889 $51.5 Million
Q1 2024

May 14, 2024

SELL
$23.82 - $32.8 $2.06 Million - $2.84 Million
-86,600 Reduced 4.29%
1,929,700 $53.1 Million
Q4 2023

Jan 31, 2024

BUY
$23.16 - $32.34 $5.67 Million - $7.91 Million
244,722 Added 13.81%
2,016,300 $61.5 Million
Q3 2023

Nov 13, 2023

SELL
$31.62 - $45.78 $7.86 Million - $11.4 Million
-248,501 Reduced 12.3%
1,771,578 $56 Million
Q1 2023

May 08, 2023

SELL
$33.3 - $44.82 $2.88 Million - $3.88 Million
-86,566 Reduced 4.11%
2,020,079 $75.3 Million
Q4 2022

Feb 13, 2023

BUY
$33.21 - $62.69 $19.7 Million - $37.1 Million
592,045 Added 39.09%
2,106,645 $73.5 Million
Q3 2022

Nov 14, 2022

BUY
$53.92 - $71.7 $5.19 Million - $6.9 Million
96,300 Added 6.79%
1,514,600 $84.8 Million
Q2 2022

Aug 15, 2022

BUY
$38.49 - $76.21 $30.7 Million - $60.9 Million
798,700 Added 128.91%
1,418,300 $73.4 Million
Q1 2022

May 13, 2022

BUY
$58.27 - $118.99 $4.03 Million - $8.24 Million
69,210 Added 12.57%
619,600 $45 Million
Q4 2021

Feb 14, 2022

SELL
$100.76 - $138.36 $15.8 Million - $21.6 Million
-156,440 Reduced 22.13%
550,390 $65.1 Million
Q3 2021

Nov 15, 2021

SELL
$132.37 - $176.78 $6.11 Million - $8.17 Million
-46,192 Reduced 6.13%
706,830 $94.8 Million
Q2 2021

Aug 16, 2021

BUY
$60.88 - $161.91 $5.6 Million - $14.9 Million
92,037 Added 13.92%
753,022 $122 Million
Q1 2021

May 13, 2021

BUY
$46.59 - $83.68 $7.53 Million - $13.5 Million
161,626 Added 32.37%
660,985 $53 Million
Q4 2020

Feb 12, 2021

BUY
$18.83 - $63.53 $7.17 Million - $24.2 Million
380,640 Added 320.62%
499,359 $27.2 Million
Q3 2020

Nov 12, 2020

BUY
$17.47 - $24.93 $739,470 - $1.06 Million
42,328 Added 55.41%
118,719 $2.36 Million
Q2 2020

Aug 13, 2020

BUY
$11.14 - $22.87 $850,995 - $1.75 Million
76,391 New
76,391 $1.61 Million
Q2 2019

Aug 14, 2019

SELL
$13.88 - $18.41 $9.26 Million - $12.3 Million
-667,000 Closed
0 $0
Q4 2018

Feb 13, 2019

SELL
$11.39 - $27.13 $5,979 - $14,243
-525 Reduced 0.08%
667,000 $9.1 Million
Q3 2018

Nov 13, 2018

BUY
$25.78 - $32.6 $1.09 Million - $1.38 Million
42,225 Added 6.75%
667,525 $19.1 Million
Q2 2018

Aug 10, 2018

BUY
$20.02 - $30.79 $544,544 - $837,488
27,200 Added 4.55%
625,300 $17.1 Million
Q1 2018

May 09, 2018

BUY
$19.43 - $34.95 $3.85 Million - $6.92 Million
198,100 Added 49.53%
598,100 $12.6 Million
Q4 2017

Feb 14, 2018

BUY
$17.39 - $31.12 $6.96 Million - $12.4 Million
400,000
400,000 $0

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $926M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.